HRMY Biotechnology · Rare disease · CNS drugs · Single product · Thesis updated July 19, 2026

WAKIX funds the next act

Harmony’s business still depends on WAKIX, its narcolepsy drug and current sole revenue source.
Q1 2026 WAKIX net revenue was $215.4 million, up 17% year over year.
Management kept 2026 net revenue guidance at $1.0 billion to $1.04 billion.
The next key step is the Pitolisant GR NDA filing, with a target PDUFA date in Q1 2027.
The main risk is that generic lawsuits or new sleep drugs hit WAKIX before the pipeline is ready.

01 Running thesis

One strong drug, many clocks

Harmony is a rare brain disease drug company, but the stock is still mostly a WAKIX story. WAKIX treats narcolepsy, a sleep disorder that can cause extreme daytime sleepiness and sudden muscle weakness. In Q1 2026, WAKIX net revenue reached $215.4 million, and management kept full-year 2026 guidance at $1.0 billion to $1.04 billion.

The bull case is simple. WAKIX keeps growing, the company protects the patents, and that cash pays for new versions of pitolisant plus new rare epilepsy drugs. Harmony also had about $878 million in cash, which gives it room to buy or license assets that could bring revenue in the 2028 to 2032 period.

The bear case is timing. WAKIX is doing the heavy lifting while several pipeline assets are still waiting on data or FDA review. Patent cases, including the new AET Pharma and Sandoz lawsuit, could change the generic entry timeline. New orexin agonist drugs could also take share in sleep disorders if they work better or faster.

Finn’s overall view is balanced, not glowing. Growth and financial health look solid, but sentiment is weaker because investors still need proof that Harmony can become more than one big product.

May 2026▲Q1 2026 WAKIX net revenue reached $215.4 million, up 17% year over year, and management kept 2026 guidance at $1.0 billion to $1.04 billion. Harmony also added a new AET Pharma and Sandoz patent lawsuit and confirmed key mid-2026 pipeline steps.

Feb 2026▲Full-year 2025 WAKIX sales reached $868.5 million, and 2026 guidance crossed the $1 billion mark. Settlements with 6 of 7 original generic filers improved the expected protection window, though EPX-100 data moved to H1 2027.

Nov 2025→WAKIX outperformed, with Q3 2025 net revenue of $239.5 million and higher full-year guidance. The gain was offset by the ZYN-002 Phase 3 failure in Fragile X syndrome.

May 2025▲Q1 2025 WAKIX revenue grew 20% year over year to $184.7 million, and management kept full-year 2025 guidance at $820 million to $860 million. Major pipeline timelines were still on track at that point.

Feb 2025▼The FDA refused to file the WAKIX idiopathic hypersomnia application, delaying that growth path. Strong 2024 WAKIX revenue of $714.7 million and the first generic settlement softened the hit.

Oct 2024▲The initial thesis formed around a strong WAKIX base and a rare CNS pipeline. Q3 2024 WAKIX net revenue was $186 million, and management kept 2024 guidance at $700 million to $720 million.

02 Business model

WAKIX pays the bills

Harmony makes money by selling prescription medicine in the United States. Today, that means WAKIX. The company reports one business segment, and all current revenue comes from net product sales of WAKIX.

WAKIX is non-scheduled, meaning it is not treated as a controlled substance under federal drug scheduling. That helps set it apart in narcolepsy, where some treatments have stricter handling rules. Harmony’s commercial job is to add patients, keep doctors using WAKIX, and defend pricing and coverage.

The strategy is to stretch the pitolisant franchise through new formulations such as Pitolisant GR and Pitolisant HD. At the same time, Harmony is trying to add new engines in rare epilepsy and other CNS diseases. CNS means central nervous system, which includes the brain and spinal cord.

Where it breaks is concentration. If WAKIX slows, loses patent protection earlier than expected, or faces a better new class of drugs, the company has fewer backup revenue streams today.

03 Product portfolio

What Harmony owns

Cash cow

WAKIX

WAKIX is pitolisant for narcolepsy in adult and pediatric patients age 6 and older. It is Harmony’s only commercial product and its sole revenue source.

Growth engine

Pitolisant GR

Pitolisant GR is a gastro-resistant version of pitolisant. Harmony says the NDA filing is on track for Q2 2026, with a target FDA decision date in Q1 2027.

Option

Pitolisant HD

Pitolisant HD is a higher-dose formulation being tested in Phase 3 trials for narcolepsy and idiopathic hypersomnia. Topline data are expected in 2027, with a target FDA decision in 2028.

Option

New pitolisant formulation

Harmony is developing a new pitolisant formulation for broader CNS uses outside sleep and wake disorders. Q1 2026 license deals with Novitium and MSN added intellectual property to support this plan.

Option

BP1.15205

BP1.15205 is an orexin-2 receptor agonist, a drug type aimed at wakefulness biology. Phase 1 single-ascending-dose PK data are expected in mid-2026.

Option

EPX-100

EPX-100 is in Phase 3 trials for Dravet syndrome and Lennox-Gastaut syndrome, two rare epilepsy disorders. Topline Dravet data are expected in H1 2027, later than the first hoped-for diversification catalyst.

Option

ZYN-002

ZYN-002, also called Zygel, failed its Phase 3 RECONNECT trial in Fragile X syndrome. The program is paused while Harmony reviews the data.

04 Business segments

Reported as one business

WAKIX net product sales100%growing fast

Pipeline and other revenue0%flat

Harmony reports one integrated pharmaceutical segment. For Q1 2026, all current revenue came from WAKIX net product sales in the United States, while the pipeline produced no product revenue.

05 Risk factors

What could break the story

Patent cliff moves closer

High impact · Medium odds

Harmony has settled with 6 of the 7 original generic filers, with generic entry no sooner than March 2030 if pediatric exclusivity is granted. One original filer remains, and Harmony also filed a new lawsuit against AET Pharma and Sandoz tied to an amorphous pitolisant patent. A bad ruling could pull forward generic WAKIX risk before new products are ready.

We watchCourt updates in the remaining original ANDA case, the AET Pharma and Sandoz case, and any change to the February 2027 stay.

WAKIX growth slows

High impact · Medium odds

The 2026 plan depends on WAKIX reaching $1.0 billion to $1.04 billion in net revenue. If patient adds slow, payer access worsens, or prescriptions flatten, Harmony’s cash engine weakens. That would make pipeline funding and dealmaking harder.

We watchQuarterly WAKIX net revenue versus guidance, patient add commentary, and any change to full-year 2026 revenue guidance.

Orexin competition changes sleep medicine

Medium impact · Medium odds

New orexin agonists could become important competitors in sleep and wake disorders. Harmony has its own orexin-2 agonist, BP1.15205, but it still needs human data. If rival drugs show better results first, WAKIX and Harmony’s pipeline could face a tougher market.

We watchMid-2026 Phase 1 PK data for BP1.15205 and clinical updates from competing orexin agonist programs.

Pipeline data disappoints

High impact · Medium odds

The ZYN-002 Phase 3 failure already showed that Harmony’s pipeline carries real clinical risk. The next major diversification readouts include the Phase 3 TEMPO study in Prader-Willi syndrome in H2 2026 and EPX-100 Dravet data in H1 2027. Failure would leave the company more tied to WAKIX.

We watchTopline TEMPO data in H2 2026 and EPX-100 Phase 3 Dravet data in H1 2027.

Trial timelines slip

Medium impact · Medium odds

Harmony is running or planning several studies in rare CNS conditions. Rare disease trials can be hard to enroll because patient groups are small and other studies compete for the same people. Delays in Pitolisant HD or EPX-100 would push new revenue further out.

We watchEnrollment updates for Pitolisant HD ONSTRIDE studies and EPX-100 Phase 3 trials.

Deals do not fill the gap

Medium impact · Medium odds

Management wants business development assets that could generate revenue in the 2028 to 2032 window. Harmony has cash, but good near-commercial rare disease assets can be expensive. Paying too much or buying weak data would hurt returns.

We watchAny acquisition or licensing deal, its upfront cost, clinical stage, and expected launch window.

06 Quick answers

In one breath

What does Harmony Biosciences sell?

Harmony sells WAKIX, a narcolepsy drug. It is approved for excessive daytime sleepiness and cataplexy in adult and pediatric patients age 6 and older.

Why is WAKIX so important to HRMY stock?

WAKIX is Harmony’s only commercial product and sole revenue source. Its cash flow funds new pitolisant versions, rare epilepsy trials, and possible acquisitions.

What are Harmony’s biggest upcoming catalysts?

Key events include the Pitolisant GR NDA filing in Q2 2026, BP1.15205 Phase 1 PK data in mid-2026, TEMPO Phase 3 data in H2 2026, and EPX-100 Dravet data in H1 2027.

What is the biggest risk for Harmony Biosciences?

The biggest risk is that WAKIX loses momentum or faces generic competition earlier than expected. That would matter most if pipeline products are not ready to replace the revenue.